|
Balance Sheet Cash Flow Statement 3721 Valley Centre Dr., Ste. 500 San Diego, CA 92130 CA Tel. 858-480-0400 Fax 858-509-1761 |
Type: Public
On the web:
http://www.somaxon.com
Employees:
22
If Somaxon Pharmaceuticals is successful in bringing its drugs to market, Las Vegas may see a decline in cigarette-smoking, insomniac gamblers. The vice-busting company's lead product candidate, Silenor, is under development for the treatment of insomnia. A second product, nalmefene, is being developed to treat compulsive disorders such as gambling, kleptomania, pyromania, and compulsive spending; the company is also looking into its effectiveness as a smoking cessation drug. Somaxon is focused on developing and bringing to market treatments for psychological and neurological disorders.
Key numbers for fiscal year ending December, 2008:
Sales: $0.0M
Net income: ($37.2)M
Officers:
Chairman: David F. Hale
President, CEO, CFO, and Director: Richard W. Pascoe
SVP Sales and Marketing: Jeffrey W. (Jeff) Raser
Competitors:
GlaxoSmithKline
Sanofi-Aventis
Sepracor
